Clinical effect not specified
Source: DDInter
Nonselective α adrenergic receptor antagonist (competitive) · Antihypertensive, Alpha Blocker
Phentolamine is a competitive α adrenergic receptor antagonist. It causes a progressive decrease in peripheral resistance due to antagonism of α adrenergic receptors in the vasculature and increases cardiac output due to reflex sympathetic stimulation and enhanced norepinephrine release (due to presynaptic α2 blockade).
C
Clinical effect not specified
Source: DDInter
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Management of tachycardia caused by phentolamine.
A beta blocker may be added with phentolamine.
Source: KDT 7e · p573
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team